Table 2.
Antiproliferative effect and cytotoxicity of 1–2 against mammalian cell ines.
| Cell Line | Compound | Positive Control | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | Epothilone B | Imatinib | |
| Cytotoxicity a IC50 (μM) | |||||
| Mouse fibroblast L929 | 4.16 | 5.18 | N.D. | 1.4 × 10−3 | N.D. |
| HeLa cells KB3.1 | 1.80 | 1.83 | N.D. | 8.9 × 10−5 | N.D. |
| Human breast adenocarcinoma MCF-7 | 1.86 | 1.79 | N.D. | 2.4 × 10−4 | N.D. |
| Human lung carcinoma A549 | 7.32 | 6.91 | N.D. | 6.9 × 10−5 | N.D. |
| Human prostate cancer PC-3 | 11.28 | 2.81 | N.D. | 1.6 × 10−3 | N.D. |
| Ovarian carcinoma SKOV-3 | 1.84 | 1.55 | N.D. | 2.8 × 10−4 | N.D. |
| Squamous cell carcinoma A431 | 2.17 | 1.60 | N.D. | 7.9 × 10−5 | N.D. |
| Antiproliferative Effect b GI50 (µM) | |||||
| HUVEC | 4.55 | 1.08 | 8.31 | N.D. | 18.5 |
| Myelogenous leukemia K-562 | 8.31 | 3.67 | 3.34 | N.D. | 0.17 |
a MTT assay, b CellTiter blue assay. The starting concentration for the cytotoxicity assay was 300 μg/mL, and substances were dissolved in MeOH (1 mg/mL). MeOH was used as the negative control and showed no activity against the tested mammalian cell lines. Results were expressed as IC50: half-maximal inhibitory concentration, CC50: half-maximal cytotoxicity concentration, GI50: half-maximal cell proliferation (μM), N.D: not determined.